Related Experiment Video
Updated: Jun 7, 2026
Ultrasound Imaging-guided Intracardiac Injection to Develop a Mouse Model of Breast Cancer Brain Metastases Followed by Longitudinal MRI
Published on: March 6, 2014
Heading in a new direction: drug permeability in breast cancer brain metastasis
1Indiana University Simon Cancer Center, Indianapolis, Indiana, USA. gsledge@iupui.edu
Abstract:
Systemic therapies for breast cancer brain metastasis are largely unsuccessful. Mouse models of brain metastasis show significant heterogeneity in uptake of paclitaxel and doxorubicin, with average levels more than those seen in normal brain tissue, but significantly less than in metastases to other organs.
Insights
Systemic therapies for breast cancer brain metastasis show limited success. Mouse models reveal inconsistent drug uptake in brain tumors, which is lower than in other metastatic sites.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Systemic therapies for breast cancer brain metastasis (BCBM) are largely unsuccessful.
- Significant heterogeneity exists in the uptake of chemotherapy drugs within BCBM mouse models.
Discussion:
- Average uptake of paclitaxel and doxorubicin in BCBM mouse models exceeds that of normal brain tissue.
- However, drug levels in brain metastases are considerably lower compared to metastases in other organs.
Key Insights:
- Chemotherapy drug penetration into brain metastases is variable and often insufficient.
- This heterogeneity contributes to the limited efficacy of systemic treatments for BCBM.
Outlook:
- Further research is needed to understand the mechanisms of drug resistance and transport in BCBM.
- Developing strategies to enhance drug delivery to the brain is crucial for improving treatment outcomes.
